$9.34
-0.19 (-1.99%)
Open$9.68
Previous Close$9.53
Day High$9.68
Day Low$9.00
52W High$16.93
52W Low$8.48
Volume—
Avg Volume11.9K
Market Cap52.82M
P/E Ratio—
EPS$-2.40
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+113.8% upside
Current
$9.34
$9.34
Target
$19.97
$19.97
$17.96
$19.97 avg
$26.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.10M | 46.49M | 39.49M |
| Net Income | 3.70M | 3.34M | 2.56M |
| Profit Margin | 8.2% | 7.2% | 6.5% |
| EBITDA | 5.80M | 5.78M | 5.15M |
| Free Cash Flow | 3.02M | 2.12M | 2.20M |
| Rev Growth | +4.3% | +20.2% | +6.0% |
| Debt/Equity | 0.88 | 1.05 | 1.14 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |